Alzheimer’s: a new research blood method for measuring tau burden
A JAMA study links a new immunoassay with advanced brain pathology. The method remains at the research stage.

A new laboratory method for measuring blood eMTBR-tau was associated with the burden of abnormal tau protein in the brain, according to a study published in JAMA on 16 November 2026. The finding mainly concerns advanced pathology characteristic of Alzheimer’s disease.
Researchers studied 728 people across four cohorts in the United States, Canada and Sweden. For 521 brain donors, blood collected during life was compared with postmortem findings. Another 207 belonged to cohorts using tau PET imaging.
The new immunoassay requires a smaller plasma sample than the mass spectrometry method previously used for this particular marker. This could facilitate larger studies and further validation across more laboratories.
The analysis was cross-sectional, involving selected research cohorts with limited population diversity. It does not establish an individual prediction of disease progression. Banner Health clarifies that the test is not yet available for clinical use and is not intended as a standalone diagnosis. Further prospective studies are needed.
The study discloses some authors’ financial relationships with companies involved in developing the method or performing measurements.
English translation of the Greek edition · Read in Greek